Back to discover
Disease

Candidemia

Late-stage therapeutic developmentEmerging research
MeSHCandidemia
1
Publications
11
Clinical trials
2024
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q1 2028.
Upcoming Milestones
Clinical Milestones3View
Results expected 1
Recently completed 1
Other updates 1
Activity timeline3

Clinical trials

8 sponsors · 0 new · 1 completed in the last 12 months (net -1)

The current development programme across all trial phases.

Clinical programme
11
All trials
1
Active
10
Late-stage
6
Completed
Late-stage studies

An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis

Phase 3 · Recruiting · Basilea Pharmaceutica

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Phase 3 · Completed · Scynexis, Inc.

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Phase 3 · Completed · Mundipharma Research Limited

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections

Phase 3 · Completed · Astellas Pharma Inc

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase 3 · Completed · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA

Phase 3 · Completed · Pfizer
Recently completed

A Phase 3, Multicenter, Randomized, Double-Blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (The ReSPECT Study)

Phase 3 · Completed · Mundipharma Research Limited

Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral Ibrexafungerp (SCY-078) as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris

Phase 3 · Completed · Scynexis, Inc.

A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis

Phase 3 · Completed · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA

Phase 3 · Completed · Pfizer

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus a Caspofungin Followed by Voriconazole Regimen in the Treatment of Candidemia and Other Invasive Candida Infections

Phase 3 · Completed · Astellas Pharma Inc

A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in ICU Patients

Phase 4 · Completed · Universidade Federal do Rio de Janeiro

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

<i>Candida albicans</i> and <i>Candida glabrata</i>: global priority pathogens.

Microbiology and molecular biology reviews : MMBR · 2024 · 89 cites
Recent publications

<i>Candida albicans</i> and <i>Candida glabrata</i>: global priority pathogens.

Microbiology and molecular biology reviews : MMBR · 2024 · 89 cites
Major themes5
  • Antifungal Agents1
  • Candida albicans1
  • Candida glabrata1
  • Candidiasis1
  • Drug Resistance, Fungal1
Leading journals1
  • Microbiology and molecular biology reviews : MMBR1
Leading researchers6
  • Brunke S1
  • Gow NAR1
  • Hube B1
  • Katsipoulaki M1
  • Malavia-Jones D1
  • Stappers MHT1
Affiliations (unnormalised)3
  • Hans Knoell Institute1
  • Institute of Microbiology1
  • MRC Centre for Medical Mycology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A form of invasive candidiasis where species of CANDIDA are present in the blood.

Identifiers
MeSHCandidemia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.